Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
44
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Monohon Ted | Chief Accounting Officer & VP | 5 | $0 | $0 | 2022-06-29 |
| Bray June | Director | 1 | $0 | $0 | 2022-06-09 |
| McLoughlin Margaret | Director | 18 | $9.3K | $691.9K | 2022-06-08 |
| Lamond David | Director | 28 | $8.05M | $0 | 2022-06-08 |
| Senner Christopher J. | Director | 3 | $0 | $0 | 2022-06-08 |
| RYAN UNA S | Director | 4 | $48.9K | $0 | 2022-06-08 |
| Holsinger Leslie | Executive Vice President | 17 | $0 | $1.23M | 2022-06-06 |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | 7 | $0 | $30.9K | 2022-06-06 |
| Hannah Brendan | Chief Business Officer | 4 | $0 | $0 | 2022-05-23 |
| Smith Karen L. | Chief Medical Officer | 4 | $0 | $0 | 2022-05-23 |
| Thye Dirk | Chief Executive Officer | 4 | $0 | $0 | 2022-05-23 |
| Low Philip S | Director | 3 | $0 | $0 | 2022-05-19 |
| Sabbagh Marwan | Director | 1 | $0 | $0 | 2022-03-14 |
| Detke Michael J. | Chief Medical Officer | 26 | $0 | $4.15M | 2022-03-03 |
| LOWE CHRISTOPHER P. | Interim CEO, COO & CFO | 29 | $0 | $3.67M | 2022-03-03 |
| Dominy Stephen S. | Chief Scientific Officer | 5 | $11.0K | $0 | 2022-01-03 |
| Lynch Casey | Chief Executive Officer | 31 | $0 | $4.41M | 2022-01-03 |
| Boeding Chad | Other | 12 | $1.20M | $0 | 2020-06-12 |
| YOUNG KEVIN | Director | 2 | $510.0K | $0 | 2020-06-08 |
| Pfizer Strategic Investment Holdings LLC | 10% Owner | 1 | $0 | $14.87M | 2020-06-03 |
| Gafric Kristen | SVP, Legal & Administration | 2 | $0 | $0 | 2020-02-06 |
| EPIQ Capital Group, LLC | Other | 13 | $557.9K | $0 | 2019-08-21 |
| Pfizer Ventures (US) LLC | 10% Owner | 7 | $850.0K | $0 | 2019-05-13 |
| Lamond Christine | 10% Owner | 8 | $0 | $0 | 2019-05-13 |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | 3 | $0 | $0 | 2019-05-13 |
| Maetzel Andreas | VP, Clinical and Regulatory | 4 | $0 | $0 | 2014-02-03 |
| Shawver Laura | Director | 4 | $0 | $0 | 2014-02-03 |
| McBean Kenneth | President | 8 | $0 | $0 | 2014-02-03 |
| Vecchia Marco | Director | 6 | $0 | $0 | 2014-02-03 |
| Duarte Ira | Principal Accounting Officer | 7 | $0 | $0 | 2014-02-03 |
| Stephan Robert | Director | 6 | $0 | $0 | 2014-02-03 |
| Failla Anton Giorgio | Director | 6 | $0 | $0 | 2014-02-03 |
| Chiesi Farmaceutici SpA | 10% Owner | 7 | $118.76M | $0 | 2014-02-03 |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | 15 | $0 | $438.1K | 2014-02-03 |
| Heffernan Michael Thomas | Director | 9 | $0 | $0 | 2014-02-03 |
| Enright Michael David | Director | 8 | $0 | $0 | 2014-02-03 |
| CODEANNE CHRISTOPHER GEORGE | Director | 8 | $0 | $0 | 2014-02-03 |
| Collard Craig A | Chief Executive Officer | 12 | $0 | $9.02M | 2014-02-03 |
| Roberts Alan | VP, Scientific Affairs | 9 | $0 | $0 | 2014-02-03 |
| Harper James A | Director | 6 | $0 | $0 | 2014-02-03 |
| MCEWAN ALASTAIR STUART | CFO and Treasurer | 4 | $0 | $0 | 2014-02-03 |
| Powell Andrew Kenneth William | EVP, General Counsel | 4 | $0 | $0 | 2013-08-30 |
| Morgus Vincent T. | EVP, Finance and CFO | 4 | $0 | $0 | 2012-08-22 |
| Chiesi Alessandro | Director | 1 | $0 | $0 | 2012-05-22 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Monohon Ted | Chief Accounting Officer & V | A Award deriv | 2022-06-29 | 2022-07-01 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Bray June | Director | A Award deriv | 2022-06-09 | 2022-06-10 | 54,000 | — | $0 | 54,000 | SEC↗ |
| McLoughlin Margaret | Director | A Award deriv | 2022-06-08 | 2022-06-09 | 27,000 | — | $0 | 27,000 | SEC↗ |
| Lamond David | Director | A Award deriv | 2022-06-08 | 2022-06-09 | 27,000 | — | $0 | 27,000 | SEC↗ |
| RYAN UNA S | Director | A Award deriv | 2022-06-08 | 2022-06-09 | 27,000 | — | $0 | 27,000 | SEC↗ |
| Senner Christopher J. | Director | A Award deriv | 2022-06-08 | 2022-06-09 | 27,000 | — | $0 | 27,000 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | S Sale | 2022-06-06 | 2022-06-08 | 10,800 | $2.86 | $30.9K | 122,500 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | F Tax w/h | 2022-06-06 | 2022-06-08 | 6,700 | $2.86 | $19.2K | 133,300 | SEC↗ |
| Holsinger Leslie | EVP, Preclinical Development | F Tax w/h | 2022-06-06 | 2022-06-08 | 10,920 | $2.86 | $31.2K | 148,080 | SEC↗ |
| Monohon Ted | Chief Accounting Officer & V | F Tax w/h | 2022-06-06 | 2022-06-08 | 1,529 | $3.12 | $4.8K | 32,471 | SEC↗ |
| Hannah Brendan | Chief Business Officer | A Award deriv | 2022-05-23 | 2022-05-23 | 353,656 | — | $0 | 353,656 | SEC↗ |
| Smith Karen L. | Chief Medical Officer | A Award deriv | 2022-05-23 | 2022-05-23 | 1,365,449 | — | $0 | 1,365,449 | SEC↗ |
| Thye Dirk | Chief Executive Officer | A Award deriv | 2022-05-23 | 2022-05-23 | 1,979,650 | — | $0 | 1,979,650 | SEC↗ |
| Hannah Brendan | Chief Business Officer | A Award deriv | 2022-05-19 | 2022-05-23 | 103,500 | — | $0 | 103,500 | SEC↗ |
| Low Philip S | Director | A Award deriv | 2022-05-19 | 2022-05-23 | 22,058 | — | $0 | 22,058 | SEC↗ |
| Smith Karen L. | Chief Medical Officer | A Award deriv | 2022-05-19 | 2022-05-23 | 151,799 | — | $0 | 151,799 | SEC↗ |
| Thye Dirk | Chief Executive Officer | A Award deriv | 2022-05-19 | 2022-05-23 | 206,391 | — | $0 | 206,391 | SEC↗ |
| Hannah Brendan | Chief Business Officer | A Award | 2022-05-19 | 2022-05-23 | 16,224 | — | $0 | 16,224 | SEC↗ |
| Lamond David | Director | A Award | 2022-05-19 | 2022-05-23 | 200,002 | — | $0 | 1,734,722 | SEC↗ |
| Low Philip S | Director | A Award | 2022-05-19 | 2022-05-23 | 63,974 | — | $0 | 63,974 | SEC↗ |
| Low Philip S | Director | A Award | 2022-05-19 | 2022-05-23 | 455,309 | — | $0 | 455,309 | SEC↗ |
| Smith Karen L. | Chief Medical Officer | A Award | 2022-05-19 | 2022-05-23 | 24,336 | — | $0 | 24,336 | SEC↗ |
| Thye Dirk | Chief Executive Officer | A Award | 2022-05-19 | 2022-05-23 | 64,589 | — | $0 | 64,589 | SEC↗ |
| Hannah Brendan | Chief Business Officer | A Award | 2022-05-19 | 2022-05-27 | 113,569 | — | $0 | 129,793 | SEC↗ |
| Thye Dirk | Chief Executive Officer | A Award | 2022-05-19 | 2022-05-27 | 216,322 | — | $0 | 280,911 | SEC↗ |
| Smith Karen L. | Chief Medical Officer | A Award | 2022-05-19 | 2022-05-27 | 170,354 | — | $0 | 194,690 | SEC↗ |
| Sabbagh Marwan | Director | A Award deriv | 2022-03-14 | 2022-03-16 | 22,058 | — | $0 | 22,058 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | A Award | 2022-03-03 | 2022-03-04 | 140,000 | — | $0 | 140,000 | SEC↗ |
| Holsinger Leslie | EVP, Preclinical Development | A Award | 2022-03-03 | 2022-03-04 | 155,500 | — | $0 | 159,000 | SEC↗ |
| LOWE CHRISTOPHER P. | Interim CEO, COO & CFO | A Award | 2022-03-03 | 2022-03-04 | 175,000 | — | $0 | 265,000 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | A Award | 2022-03-03 | 2022-03-04 | 140,000 | — | $0 | 140,000 | SEC↗ |
| Monohon Ted | Chief Accounting Officer & V | A Award | 2022-03-03 | 2022-03-04 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | A Award deriv | 2022-01-03 | 2022-01-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Dominy Stephen S. | Chief Scientific Officer | A Award deriv | 2022-01-03 | 2022-01-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Holsinger Leslie | EVP, R&D | A Award deriv | 2022-01-03 | 2022-01-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | A Award deriv | 2022-01-03 | 2022-01-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | A Award deriv | 2022-01-03 | 2022-01-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Lynch Casey | Chief Executive Officer | A Award deriv | 2022-01-03 | 2022-01-05 | 440,000 | — | $0 | 440,000 | SEC↗ |
| Monohon Ted | Chief Accounting Officer | A Award deriv | 2021-12-14 | 2022-01-05 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Lynch Casey | Chief Executive Officer | M Exercise deriv | 2021-11-18 | 2021-11-19 | 60,000 | — | $0 | 23,159 | SEC↗ |
| Lynch Casey | Chief Executive Officer | M Exercise | 2021-11-18 | 2021-11-19 | 60,000 | $0.46 | $27.6K | 109,895 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-11-16 | 2021-11-16 | 30,000 | — | $0 | 103,294 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-11-16 | 2021-11-16 | 30,000 | $2.23 | $66.9K | 90,000 | SEC↗ |
| Dominy Stephen S. | Chief Scientific Officer | P Buy | 2021-11-12 | 2021-11-12 | 763 | $14.40 | $11.0K | 1,217,086 | SEC↗ |
| McLoughlin Margaret | Director | M Exercise deriv | 2021-10-08 | 2021-10-12 | 1,000 | — | $0 | 84,911 | SEC↗ |
| McLoughlin Margaret | Director | M Exercise | 2021-10-08 | 2021-10-12 | 1,000 | $17.00 | $17.0K | 1,000 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-10-08 | 2021-10-12 | 1,000 | $88.93 | $88.9K | 0 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-10-05 | 2021-10-07 | 4,963 | — | $0 | 95,037 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-10-05 | 2021-10-07 | 4,963 | $54.85 | $272.2K | 64,963 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-10-05 | 2021-10-07 | 4,963 | $98.50 | $488.9K | 60,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-08-17 | 2021-08-18 | 30,000 | — | $0 | 133,294 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-08-17 | 2021-08-18 | 30,000 | $2.23 | $66.9K | 60,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-08-16 | 2021-08-18 | 22,000 | — | $0 | 163,294 | SEC↗ |
| McLoughlin Margaret | Director | M Exercise deriv | 2021-08-16 | 2021-08-18 | 6,000 | — | $0 | 85,911 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-08-16 | 2021-08-18 | 2,330 | $96.32 | $224.4K | 33,177 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-08-16 | 2021-08-18 | 22,000 | $2.23 | $49.1K | 52,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-08-16 | 2021-08-18 | 9,158 | $94.23 | $863.0K | 42,842 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-08-16 | 2021-08-18 | 7,335 | $95.02 | $697.0K | 35,507 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-08-16 | 2021-08-18 | 2,077 | $98.90 | $205.4K | 30,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-08-16 | 2021-08-18 | 1,100 | $97.28 | $107.0K | 32,077 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-08-16 | 2021-08-18 | 48 | $98.90 | $4.7K | 0 | SEC↗ |
| McLoughlin Margaret | Director | M Exercise | 2021-08-16 | 2021-08-18 | 6,000 | $17.00 | $102.0K | 6,000 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-08-16 | 2021-08-18 | 3,056 | $94.55 | $288.9K | 2,944 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-08-16 | 2021-08-18 | 1,044 | $95.57 | $99.8K | 1,900 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-08-16 | 2021-08-18 | 1,429 | $96.51 | $137.9K | 471 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-08-16 | 2021-08-18 | 423 | $97.55 | $41.3K | 48 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2021-08-10 | 2021-08-12 | 10,000 | — | $0 | 92,352 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2021-08-10 | 2021-08-12 | 10,000 | $2.23 | $22.3K | 10,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-08-10 | 2021-08-12 | 10,000 | $100.00 | $1.00M | 0 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2021-07-07 | 2021-07-07 | 17,400 | — | $0 | 102,352 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2021-07-07 | 2021-07-07 | 17,400 | $2.23 | $38.8K | 17,400 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-07 | 6,942 | $56.27 | $390.6K | 523 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-07 | 4,353 | $55.38 | $241.1K | 7,465 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-07 | 1,648 | $54.37 | $89.6K | 11,818 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-07 | 3,934 | $53.24 | $209.4K | 13,466 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-07 | 523 | $56.99 | $29.8K | 0 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2021-07-06 | 2021-07-07 | 12,600 | — | $0 | 119,752 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-07 | 288 | $55.01 | $15.8K | 0 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-07 | 8,260 | $53.91 | $445.3K | 288 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-07 | 32,313 | $53.43 | $1.73M | 8,548 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2021-07-06 | 2021-07-07 | 12,600 | $2.23 | $28.1K | 40,861 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-06-30 | 2021-06-30 | 30,000 | — | $0 | 185,294 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-06-30 | 2021-06-30 | 30,000 | $2.23 | $66.9K | 30,000 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise deriv | 2021-06-28 | 2021-06-30 | 20,000 | — | $0 | 215,594 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-06-28 | 2021-06-29 | 100 | $55.73 | $5.6K | 0 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-06-28 | 2021-06-29 | 250 | $55.03 | $13.8K | 100 | SEC↗ |
| McLoughlin Margaret | Director | S Sale | 2021-06-28 | 2021-06-29 | 200 | $55.01 | $11.0K | 350 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-06-28 | 2021-06-30 | 1,044 | $56.16 | $58.6K | 0 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-06-28 | 2021-06-30 | 4,153 | $55.11 | $228.9K | 1,044 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-06-28 | 2021-06-30 | 7,079 | $54.13 | $383.2K | 5,197 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | S Sale | 2021-06-28 | 2021-06-30 | 7,724 | $53.39 | $412.4K | 12,276 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | M Exercise | 2021-06-28 | 2021-06-30 | 20,000 | $2.23 | $44.6K | 20,000 | SEC↗ |
| Lamond David | Director | A Award deriv | 2021-06-16 | 2021-06-17 | 11,029 | — | $0 | 11,029 | SEC↗ |
| McLoughlin Margaret | Director | A Award deriv | 2021-06-16 | 2021-06-17 | 11,029 | — | $0 | 11,029 | SEC↗ |
| RYAN UNA S | Director | A Award deriv | 2021-06-16 | 2021-06-17 | 11,029 | — | $0 | 11,029 | SEC↗ |
| Senner Christopher J. | Director | A Award deriv | 2021-06-16 | 2021-06-17 | 11,029 | — | $0 | 11,029 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-05-10 | 2021-05-12 | 183 | $36.73 | $6.7K | 978,774 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-05-10 | 2021-05-12 | 6,315 | $35.81 | $226.1K | 978,957 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-05-10 | 2021-05-12 | 9,918 | $34.89 | $346.0K | 985,272 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-05-10 | 2021-05-12 | 13,584 | $33.75 | $458.5K | 995,190 | SEC↗ |
| Lamond David | Director | P Buy | 2021-03-24 | 2021-03-24 | 50,000 | $33.77 | $1.69M | 1,847,109 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-03-22 | 2021-03-23 | 18,089 | $35.85 | $648.5K | 1,009,474 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-03-22 | 2021-03-23 | 300 | $36.58 | $11.0K | 1,009,174 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-03-22 | 2021-03-23 | 400 | $36.60 | $14.6K | 1,008,774 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-03-22 | 2021-03-23 | 11,211 | $35.10 | $393.5K | 1,027,563 | SEC↗ |
| Lamond David | Director | P Buy | 2021-03-04 | 2021-03-05 | 4,100 | $36.86 | $151.1K | 1,797,109 | SEC↗ |
| Lamond David | Director | P Buy | 2021-03-04 | 2021-03-05 | 16,621 | $34.28 | $569.8K | 1,763,730 | SEC↗ |
| Lamond David | Director | P Buy | 2021-03-04 | 2021-03-05 | 13,310 | $35.00 | $465.9K | 1,777,040 | SEC↗ |
| Lamond David | Director | P Buy | 2021-03-04 | 2021-03-05 | 15,969 | $36.34 | $580.3K | 1,793,009 | SEC↗ |
| Lamond David | Director | G Gift | 2021-03-04 | 2021-03-23 | 1,534,720 | — | $0 | 1,534,720 | SEC↗ |
| LOWE CHRISTOPHER P. | COO & Chief Financial Office | A Award deriv | 2021-02-09 | 2021-02-11 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Monohon Ted | Chief Accounting Officer | A Award deriv | 2021-02-09 | 2021-02-11 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 400 | $37.39 | $15.0K | 1,058,374 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 1,600 | $38.64 | $61.8K | 1,056,774 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 856 | $39.82 | $34.1K | 1,055,918 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 2,000 | $40.84 | $81.7K | 1,053,918 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 3,100 | $41.91 | $129.9K | 1,050,818 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 1,512 | $43.10 | $65.2K | 1,049,306 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 1,900 | $44.22 | $84.0K | 1,047,406 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 8,032 | $45.00 | $361.4K | 1,039,374 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-03 | 2021-02-03 | 600 | $45.73 | $27.4K | 1,038,774 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-02 | 2021-02-03 | 5,071 | $36.75 | $186.4K | 1,058,774 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-02 | 2021-02-03 | 14,929 | $36.02 | $537.7K | 1,063,845 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 100 | $38.28 | $3.8K | 1,079,145 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 4,686 | $34.60 | $162.1K | 1,094,088 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 3,100 | $35.59 | $110.3K | 1,090,988 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 7,460 | $36.56 | $272.7K | 1,083,528 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 4,283 | $37.68 | $161.4K | 1,079,245 | SEC↗ |
| Lynch Casey | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 371 | $39.23 | $14.6K | 1,078,774 | SEC↗ |
| Holsinger Leslie | Executive Vice President | M Exercise deriv | 2020-12-14 | 2020-12-15 | 40,000 | — | $0 | 66,794 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 900 | $32.59 | $29.3K | 3,500 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 400 | $32.59 | $13.0K | 4,400 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 9,525 | $31.79 | $302.8K | 1,800 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 13,200 | $30.91 | $408.0K | 14,325 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 14,275 | $30.15 | $430.4K | 27,525 | SEC↗ |
| Holsinger Leslie | Executive Vice President | S Sale | 2020-12-14 | 2020-12-15 | 1,700 | $28.80 | $49.0K | 41,800 | SEC↗ |
| Holsinger Leslie | Executive Vice President | M Exercise | 2020-12-14 | 2020-12-15 | 40,000 | $0.27 | $10.8K | 43,500 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 75,000 | — | $0 | 75,000 | SEC↗ |
| LOWE CHRISTOPHER P. | Chief Financial Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| LOWE CHRISTOPHER P. | Chief Financial Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Dominy Stephen S. | Chief Scientific Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Dominy Stephen S. | Chief Scientific Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Lynch Casey | Chief Executive Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Lynch Casey | Chief Executive Officer | A Award deriv | 2020-12-11 | 2020-12-15 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Holsinger Leslie | Executive Vice President | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Holsinger Leslie | Executive Vice President | A Award deriv | 2020-12-11 | 2020-12-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Holsinger Leslie | Executive Vice President | M Exercise deriv | 2020-12-10 | 2020-12-14 | 3,500 | — | $0 | 106,794 | SEC↗ |
| Holsinger Leslie | Executive Vice President | M Exercise | 2020-12-10 | 2020-12-14 | 3,500 | $0.27 | $945 | 3,500 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-06-12 | 2020-06-15 | 2,440 | $44.06 | $107.5K | 2,860,967 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-06-11 | 2020-06-15 | 6,600 | $44.32 | $292.5K | 2,858,527 | SEC↗ |
| Lamond David | Director | A Award deriv | 2020-06-08 | 2020-06-09 | 11,029 | — | $0 | 11,029 | SEC↗ |
| McLoughlin Margaret | Director | A Award deriv | 2020-06-08 | 2020-06-09 | 11,029 | — | $0 | 11,029 | SEC↗ |
| RYAN UNA S | Director | A Award deriv | 2020-06-08 | 2020-06-09 | 11,029 | — | $0 | 11,029 | SEC↗ |
| Senner Christopher J. | Director | A Award deriv | 2020-06-08 | 2020-06-09 | 11,029 | — | $0 | 11,029 | SEC↗ |
| YOUNG KEVIN | Director | A Award deriv | 2020-06-08 | 2020-06-09 | 11,029 | — | $0 | 11,029 | SEC↗ |
| Lamond David | Director | P Buy | 2020-06-04 | 2020-06-08 | 10,642 | $43.32 | $461.0K | 1,722,235 | SEC↗ |
| Lamond David | Director | P Buy | 2020-06-04 | 2020-06-08 | 24,874 | $43.88 | $1.09M | 1,747,109 | SEC↗ |
| Lamond David | Director | P Buy | 2020-06-04 | 2020-06-08 | 13,609 | $42.13 | $573.3K | 1,711,593 | SEC↗ |
| Pfizer Strategic Investment Ho | 10% Owner | S Sale | 2020-06-03 | 2020-06-04 | 370,000 | $40.18 | $14.87M | 2,879,973 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2020-05-27 | 2020-05-29 | 5,515 | — | $0 | 104,091 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2020-05-27 | 2020-05-29 | 5,515 | $6.91 | $38.1K | 28,261 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-05-22 | 2020-05-22 | 2,085 | $55.90 | $116.6K | 2,851,927 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-05-21 | 2020-05-22 | 520 | $55.80 | $29.0K | 2,849,842 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-05-20 | 2020-05-22 | 417 | $57.22 | $23.9K | 2,849,322 | SEC↗ |
| Boeding Chad | Other | P Buy | 2020-05-20 | 2020-05-22 | 5,668 | $58.00 | $328.7K | 2,848,905 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-19 | 2020-05-19 | 400 | $54.09 | $21.6K | 1,659,184 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-19 | 2020-05-19 | 5,906 | $55.42 | $327.3K | 1,665,090 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-19 | 2020-05-19 | 32,894 | $56.42 | $1.86M | 1,697,984 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 1,600 | $48.96 | $78.3K | 1,657,184 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 1,000 | $50.71 | $50.7K | 1,658,184 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 500 | $52.20 | $26.1K | 1,658,684 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 100 | $53.10 | $5.3K | 1,658,784 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 985 | $48.37 | $47.6K | 1,655,584 | SEC↗ |
| Lamond David | Director | P Buy | 2020-05-15 | 2020-05-19 | 1,263 | $46.30 | $58.5K | 1,654,599 | SEC↗ |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | A Award deriv | 2020-05-14 | 2020-05-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| LOWE CHRISTOPHER P. | Chief Financial Officer | A Award deriv | 2020-05-14 | 2020-05-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Holsinger Leslie | Executive Vice President | A Award deriv | 2020-05-14 | 2020-05-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2020-04-02 | 2020-04-06 | 5,515 | — | $0 | 109,606 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2020-04-02 | 2020-04-06 | 5,515 | $6.91 | $38.1K | 22,746 | SEC↗ |
| Lamond David | Director | A Award | 2020-02-10 | 2020-02-10 | 30,000 | $50.00 | $1.50M | 1,653,336 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise deriv | 2020-02-07 | 2020-02-10 | 17,231 | — | $0 | 115,121 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | M Exercise | 2020-02-07 | 2020-02-10 | 17,231 | $6.91 | $119.1K | 17,231 | SEC↗ |
| Lynch Casey | Chief Executive Officer | A Award deriv | 2020-02-06 | 2020-02-10 | 175,000 | — | $0 | 175,000 | SEC↗ |
| LOWE CHRISTOPHER P. | Chief Financial Officer | A Award deriv | 2020-02-06 | 2020-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Holsinger Leslie | Executive Vice President | A Award deriv | 2020-02-06 | 2020-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Dominy Stephen S. | Chief Scientific Officer | A Award deriv | 2020-02-06 | 2020-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Gafric Kristen | SVP, Legal & Administration | A Award deriv | 2020-02-06 | 2020-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Detke Michael J. | Chief Medical Officer | A Award deriv | 2020-02-06 | 2020-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Boeding Chad | Other | J Other | 2020-01-29 | 2020-01-31 | 4,338 | $54.30 | $235.6K | 2,843,237 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-21 | 2019-11-29 | 420 | $24.87 | $10.4K | 2,845,940 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-21 | 2019-11-29 | 1,635 | $24.87 | $40.7K | 2,847,575 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-21 | 2019-08-21 | 1,635 | $24.87 | $40.7K | 2,834,561 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-21 | 2019-08-21 | 420 | $24.87 | $10.4K | 2,832,926 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-20 | 2019-11-29 | 600 | $25.69 | $15.4K | 2,843,210 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-20 | 2019-11-29 | 2,310 | $25.69 | $59.3K | 2,845,520 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-20 | 2019-08-21 | 2,310 | $25.69 | $59.3K | 2,832,506 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-20 | 2019-08-21 | 600 | $25.69 | $15.4K | 2,830,196 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-19 | 2019-11-29 | 2,100 | $26.50 | $55.6K | 2,842,610 | SEC↗ |
| Boeding Chad | Other | P Buy | 2019-08-19 | 2019-08-19 | 2,100 | $26.50 | $55.6K | 2,829,596 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-08-16 | 2019-11-29 | 700 | $26.37 | $18.5K | 2,840,510 | SEC↗ |
| Boeding Chad | Other | P Buy | 2019-08-16 | 2019-08-19 | 700 | $26.37 | $18.5K | 2,827,496 | SEC↗ |
| Gafric Kristen | SVP, Legal & Administration | A Award deriv | 2019-08-15 | 2019-08-15 | 75,000 | — | $0 | 75,000 | SEC↗ |
| McLoughlin Margaret | Director | P Buy | 2019-05-13 | 2020-03-12 | 550 | $17.00 | $9.3K | 550 | SEC↗ |
| RYAN UNA S | Director | P Buy | 2019-05-13 | 2020-03-12 | 2,875 | $17.00 | $48.9K | 2,875 | SEC↗ |
| YOUNG KEVIN | Director | P Buy | 2019-05-13 | 2020-03-12 | 30,000 | $17.00 | $510.0K | 30,000 | SEC↗ |
| Lamond David | Director | C Conversion deriv | 2019-05-13 | 2019-05-13 | 301,829 | — | $0 | 0 | SEC↗ |
| Lamond David | Director | C Conversion deriv | 2019-05-13 | 2019-05-13 | 699,280 | — | $0 | 0 | SEC↗ |
| Lamond David | Director | C Conversion deriv | 2019-05-13 | 2019-05-13 | 924,056 | — | $0 | 0 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 462,028 | — | $0 | 0 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 462,027 | — | $0 | 0 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 961,510 | — | $0 | 0 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 500,482 | — | $0 | 0 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 500,483 | — | $0 | 0 | SEC↗ |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 2,360,071 | — | $0 | 0 | SEC↗ |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-13 | 319,731 | — | $0 | 0 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-14 | 624,205 | — | $0 | 0 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-14 | 215,697 | — | $0 | 0 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion deriv | 2019-05-13 | 2019-05-14 | 2,360,071 | — | $0 | 0 | SEC↗ |
| Lamond David | Director | C Conversion | 2019-05-13 | 2019-05-13 | 301,829 | — | $0 | 301,829 | SEC↗ |
| Lamond David | Director | C Conversion | 2019-05-13 | 2019-05-13 | 1,623,336 | — | $0 | 1,623,336 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion | 2019-05-13 | 2019-05-13 | 961,510 | — | $0 | 961,510 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion | 2019-05-13 | 2019-05-13 | 962,510 | — | $0 | 962,510 | SEC↗ |
| Lamond Christine | 10% Owner | C Conversion | 2019-05-13 | 2019-05-13 | 962,510 | — | $0 | 962,510 | SEC↗ |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | C Conversion | 2019-05-13 | 2019-05-13 | 2,679,802 | — | $0 | 2,679,802 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion | 2019-05-13 | 2019-05-14 | 2,360,071 | — | $0 | 2,360,071 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | P Buy | 2019-05-13 | 2019-05-14 | 50,000 | $17.00 | $850.0K | 3,249,973 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion | 2019-05-13 | 2019-05-14 | 624,205 | — | $0 | 3,199,973 | SEC↗ |
| Pfizer Ventures (US) LLC | 10% Owner | C Conversion | 2019-05-13 | 2019-05-14 | 215,697 | — | $0 | 2,575,768 | SEC↗ |
| Boeding Chad | Other | P Buy | 2019-05-10 | 2019-11-29 | 80 | $27.05 | $2.2K | 2,839,810 | SEC↗ |
| Boeding Chad | Other | P Buy | 2019-05-10 | 2019-11-29 | 4,170 | $27.58 | $115.0K | 2,839,730 | SEC↗ |
| Boeding Chad | Other | P Buy | 2019-05-10 | 2019-11-29 | 4,350 | $26.41 | $114.9K | 2,835,560 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-05-10 | 2019-06-14 | 4,350 | $26.41 | $114.9K | 2,822,546 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-05-10 | 2019-06-14 | 80 | $27.05 | $2.2K | 2,826,796 | SEC↗ |
| EPIQ Capital Group, LLC | Other | P Buy | 2019-05-10 | 2019-06-14 | 4,170 | $27.58 | $115.0K | 2,826,716 | SEC↗ |
| McLoughlin Margaret | Director | A Award deriv | 2019-05-08 | 2019-05-09 | 91,911 | — | $0 | 91,911 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $6.57 | $98.5K | 0 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 10,000 | $3.53 | $35.3K | 0 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 5,833 | $2.41 | $14.1K | 0 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| CODEANNE CHRISTOPHER GEORGE | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 200,000 | $4.24 | $848.0K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 11,904 | $9.07 | $108.0K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 238,083 | $7.73 | $1.84M | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 35,712 | $5.60 | $200.0K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 50,000 | $2.41 | $120.5K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 95,000 | $4.25 | $403.8K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 95,000 | $3.76 | $357.2K | 0 | SEC↗ |
| Duarte Ira | Principal Accounting Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 7,500 | $3.76 | $28.2K | 0 | SEC↗ |
| Duarte Ira | Principal Accounting Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 20,000 | $2.22 | $44.4K | 0 | SEC↗ |
| Duarte Ira | Principal Accounting Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 20,000 | $4.25 | $85.0K | 0 | SEC↗ |
| Duarte Ira | Principal Accounting Officer | D To issuer deriv | 2014-02-03 | 2014-02-04 | 8,000 | $4.24 | $33.9K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $6.57 | $98.5K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 5,833 | $2.41 | $14.1K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 10,000 | $3.53 | $35.3K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Enright Michael David | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| Failla Anton Giorgio | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Failla Anton Giorgio | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 22,500 | $3.53 | $79.4K | 0 | SEC↗ |
| Failla Anton Giorgio | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| Failla Anton Giorgio | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | D To issuer deriv | 2014-02-03 | 2014-02-04 | 50,000 | $3.76 | $188.0K | 0 | SEC↗ |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | D To issuer deriv | 2014-02-03 | 2014-02-04 | 25,000 | $4.25 | $106.3K | 0 | SEC↗ |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | D To issuer deriv | 2014-02-03 | 2014-02-04 | 50,000 | $0.20 | $10.0K | 0 | SEC↗ |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | D To issuer deriv | 2014-02-03 | 2014-02-04 | 25,000 | $2.41 | $60.3K | 0 | SEC↗ |
| Franklin Joshua B | VP, Strategy & Bus. Dev. | D To issuer deriv | 2014-02-03 | 2014-02-04 | 35,000 | $4.24 | $148.4K | 0 | SEC↗ |
| Harper James A | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 20,000 | $3.91 | $78.2K | 0 | SEC↗ |
| Harper James A | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Harper James A | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 6,250 | $4.39 | $27.4K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 3,571 | $5.60 | $20.0K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 5,833 | $2.41 | $14.1K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 10,000 | $3.53 | $35.3K | 0 | SEC↗ |
| Heffernan Michael Thomas | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $6.57 | $98.5K | 0 | SEC↗ |
| Maetzel Andreas | VP, Clinical and Regulatory | D To issuer deriv | 2014-02-03 | 2014-02-04 | 25,000 | $1.10 | $27.5K | 0 | SEC↗ |
| McBean Kenneth | President | D To issuer deriv | 2014-02-03 | 2014-02-04 | 18,824 | $2.38 | $44.8K | 0 | SEC↗ |
| McBean Kenneth | President | D To issuer deriv | 2014-02-03 | 2014-02-04 | 56,176 | $2.38 | $133.7K | 0 | SEC↗ |
| Roberts Alan | VP, Scientific Affairs | D To issuer deriv | 2014-02-03 | 2014-02-04 | 12,500 | $3.76 | $47.0K | 0 | SEC↗ |
| Roberts Alan | VP, Scientific Affairs | D To issuer deriv | 2014-02-03 | 2014-02-04 | 50,000 | $0.20 | $10.0K | 0 | SEC↗ |
| Roberts Alan | VP, Scientific Affairs | D To issuer deriv | 2014-02-03 | 2014-02-04 | 42,500 | $4.25 | $180.6K | 0 | SEC↗ |
| Roberts Alan | VP, Scientific Affairs | D To issuer deriv | 2014-02-03 | 2014-02-04 | 50,000 | $4.24 | $212.0K | 0 | SEC↗ |
| Shawver Laura | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Shawver Laura | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 20,000 | $4.08 | $81.6K | 0 | SEC↗ |
| Stephan Robert | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Stephan Robert | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Stephan Robert | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 22,500 | $3.53 | $79.4K | 0 | SEC↗ |
| Stephan Robert | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| Vecchia Marco | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| Vecchia Marco | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| Vecchia Marco | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| Vecchia Marco | Director | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $3.53 | $53.0K | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer | 2014-02-03 | 2014-02-04 | 1,567,225 | $9.50 | $14.89M | 0 | SEC↗ |
| Collard Craig A | Chief Executive Officer | D To issuer | 2014-02-03 | 2014-02-04 | 45,000 | $9.50 | $427.5K | 0 | SEC↗ |
| Duarte Ira | Principal Accounting Officer | D To issuer | 2014-02-03 | 2014-02-04 | 7,000 | $9.50 | $66.5K | 0 | SEC↗ |